Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) Director Buys $25,000.00 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Douglas Clark Wurth purchased 12,500 shares of Bluejay Diagnostics stock in a transaction dated Saturday, March 14th. The stock was bought at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the completion of the transaction, the director directly owned 12,608 shares in the company, valued at $25,216. The trade was a 11,574.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Bluejay Diagnostics Stock Up 4.0%

NASDAQ:BJDX opened at $1.78 on Thursday. Bluejay Diagnostics, Inc. has a 12-month low of $1.62 and a 12-month high of $16.68. The firm has a market capitalization of $1.83 million, a P/E ratio of -0.15 and a beta of 0.72. The stock’s fifty day simple moving average is $1.89 and its 200-day simple moving average is $3.09.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.